Picture EBD Group Connector Personal Networking in Life Sciences 650x80
Document › Details

BioNTech AG. (12/21/17). "Press Release: BioNTech to Present at 36th Annual J.P. Morgan Healthcare Conference". Mainz.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation BioNTech AG
  Today BioNTech SE (Nasdaq: BNTX)
  Group BioNTech (Group)
  Organisation 2 ICR Inc.
  Group ICR (Group)
Products Product J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco
  Product 2 mRNA-based vaccine
Index terms Index term BioNTech–JPMorgan Chase: investor conference, 201801 supply service BioNTech presents at JP Morgan Healthcare Conference 2018
  Index term 2 BioNTech–ICR: public relations, 201712 service existent by ICR Healthcare in US
Persons Person Marett, Sean (BioNTech 202012 CBO + CCO 201506 COO before Evotec)
  Person 2 Buth, Ines-Regina (akampion 200901 before Micromet Head Investor Relations before Lion Bioscience)

BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference that is being held in San Francisco, CA from January 8-11, 2018. The Company’s presentation is scheduled for Tuesday, January 9 at 9:00 AM Pacific Standard Time.

Mr. Marett will provide an overview of the Company´s strategy as well as an update on its development programs, including its expanding clinical pipeline, in-house manufacturing capabilities, and a summary of human clinical data recently published in Nature publication on its neo-epitope based individualized mRNA cancer immunotherapeutic.

For more information, please contact:

General Inquiries:

BioNTech AG
Regina Jehle
Tel: +49 6131 9084 1273

US Media & Investor Inquiries:

ICR Healthcare
James Heins / Stephanie Carrington
Tel: +1 203 682 8251
Tel: +1 646 277 1282

International Media & Investor Inquiries:

Dr. Ludger Wess / Ines-Regina Buth
Tel: +49 40 8816 5964
Tel: +49 30 2363 2768

About BioNTech AG

BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, a member of the Roche Group, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s financial shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.

More information about BioNTech is available at

Record changed: 2021-04-27


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

More documents for BioNTech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top